Brown M R, Blanchette J O, Kohn E C
Molecular Signaling Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA.
Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Dec;14(6):901-18. doi: 10.1053/beog.2000.0134.
Angiogenesis, the formation of new vessels from pre-existing vasculature, is critical to ascites development and metastasis in ovarian cancer. Many growth factors important to ovarian cancer invasion are also prominent in its associated angiogenesis. Deregulation of normal angiogenic processes occurs with the cancer's acquisition of the ability to secrete pro-angiogenic factors. The local imbalance of endogenous angio-stimulators and angio-inhibitors promotes vascularization and vascular leak. Assessment of these pro-angiogenic growth factors and enumeration of tumour-associated microvessels have been shown to be prognosticators of ovarian cancer outcome, and may also be surrogates of ovarian cancer tumour burden and/or ascites formation. The process of angiogenesis has been targeted for therapeutics development. Ovarian cancer is a primary cancer against which these new agents are being tested. Thus, further understanding of the molecular and cell biology of angiogenesis in the context of ovarian cancer offers important directions for estimation of patient outcome and for patient treatment.
血管生成，即从已有的脉管系统形成新的血管，对于卵巢癌腹水的形成和转移至关重要。许多对卵巢癌侵袭重要的生长因子在其相关的血管生成中也很突出。随着癌症获得分泌促血管生成因子的能力，正常血管生成过程失调。内源性血管刺激因子和血管抑制因子的局部失衡促进血管形成和血管渗漏。评估这些促血管生成生长因子以及计数肿瘤相关微血管已被证明是卵巢癌预后的预测指标，也可能是卵巢癌肿瘤负荷和/或腹水形成的替代指标。血管生成过程已成为治疗药物开发的靶点。卵巢癌是正在对这些新型药物进行试验的原发性癌症。因此，在卵巢癌背景下进一步了解血管生成的分子和细胞生物学，为评估患者预后和患者治疗提供了重要方向。
